[A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini].
To observe the therapeutic effect of triclabendazole in patients with paragonimiasis skrjabini. Four patients were treated with triclabendazole at dosage of 10 mg/kg bid for 3 days and were followed up for 6-10 months. The clinical symptoms, chest X-ray, hemogram and liver function tests were observed before and after treatment. Migratory subcutaneous nodules in three patients all disappeared. Small amount of pleural effusion were absorbed in two patients. Severe headache subsided in a patient with cerebral lesion. MRI showed a bean-sized calcified spot in the right frontal region. Chest X-ray in 2 patients showed that pulmonary lesions were markedly absorbed and disappeared. There was no adverse effect of the drug. Triclabendazole has marked therapeutic effect on paragonimiasis skrjabini. It is safe in administration and well tolerated.